Ta'lim innovatsiyasi va integratsiyasi

EVALUATION OF A NATRIURETIC PEPTIDE TO OPTIMIZE THE MANAGEMENT OF COMORBID PATIENTS WITH THYROTOXICOSIS AND HEART FAILURE

Khusainova Munira Alisherovna

Uzokov Ma’rufjon Yaxshiboyevich

Bozorov Abdullo Yigitaliyevich

Ключевые слова: Key words: natriuretic peptides, chronic heart failure, comorbid patients, coronary heart disease, thyrotoxicosis, threshold level.

---

Аннотация

Objective: to determine the threshold level of natriuretic peptide to optimize the
diagnosis of heart failure in comorbid patients with thyrotoxicosis, to evaluate the
dynamics of the indicator against the background of therapy. Materials and methods:
111 patients aged 58.3± 5.6 years were divided into 4 groups: the main group — 25
patients with coronary heart disease (CHD), chronic heart failure (CHF) and
thyrotoxicosis; the first comparison group — 30 patients with CHD and CHF, without
thyrotoxicosis; the second group — 30 patients with thyrotoxicosis without CHF; The
third group consisted of 26 patients with thyrotoxicosis and coronary heart disease
without signs of CHF. Thyroid function and the level of the N-terminal fragment of the
precursor of the cerebral natriuretic peptide (NT-proBNP) were evaluated initially and
after 6 months of treatment for thyrotoxicosis, coronary heart disease and CHF. Using
ROC analysis, the threshold level of NTproBNP for the diagnosis of CHF in comorbid
patients was calculated. Results: in patients of all groups, an increased concentration
of NT-proBNP (more than 125 pg/ml) was determined, in the second group it was
225.5 (180.1; 376.1) pg/ml. Values NT-proBNP did not significantly differ in patients
of the first and third groups. The highest level of NT-proBNP was determined in the
main group — 712.1 (434.3; 893.9) pg/ml. The cut-off marker for CHF screening in
patients with coronary heart disease and thyrotoxicosis was calculated at 556.4 pg/ml
(sensitivity — 72%, specificity — 100%, accuracy — 87.2% (p<0.001)). After 6
months of treatment, the level of NT-proBNP in the second comparison group
decreased by 74% (p<0.0001), reached a normal value (64.6 (42.2;76.3)), decreased by
43% in the main group and amounted to 406.7 (309.1; 498.6) pg/ml. Conclusions: in
patients of all groups, an increased concentration of NT-proBNP was detected, the
highest in the group of patients with CHF on the background of coronary heart disease
and thyrotoxicosis. A new threshold level of NT-proBNP has been determined, which makes it possible to diagnose CHF in patients with a combination of coronary heart
disease and thyrotoxicosis – 556.4 pg/ml. 

---

Библиографические ссылки

LITERATURE

Khusainova, M. A., Eshmamatova, F. B., Ismoilova, K. T., & Mamadiyorova, M. M. (2023). METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS AS A CRITERION OF CARDIOVASCULAR RISK. Oriental renaissance: Innovative, educational, natural and social sciences, 3(1), 331-339.

Khusainova, M. A. (2023). CYSTATIN C IS AN EARLY MARKER OF DECREASED KIDNEY FUNCTION. Oriental renaissance: Innovative, educational, natural and social sciences, 3(1), 485-490.

Khusainova, M. A., Vakhidov, J. J., Khayitov, S. M., & Mamadiyorova, M. M. (2023). Cardiac arrhythmias in patients with rheumatoid arthritis. Science and Education, 4(2), 130-137.

Khusainova, M. A. (2023). Comorbidity thyrotoxicosis with coronary heart disease. Science and Education, 4(5), 205-213.

Uzokov, J. B., Khusainova, M. A., Eshmamatova, F. B., & Mamadiyorova, M. M. (2023). Correction of violations rheology of blood in ischemic heart disease. Science and Education, 4(2), 153-159.

Khusainova, M. A., Gafforov, X. X., Eshmamatova, F. B., & Khayitov, S. M. (2023). Assessment of the quality of life in patients with exogenous allergic alveolitis. Science and Education, 4(2), 145-152.

Khaydarov, S. N., Khusainova, M. A., Uzokov, J. B., & Makhmudova, K. D. (2023). Heart failure and the risk of hypoglycemia. Science and Education, 4(5), 222-231.

Khusainova, M. A., Khaydarov, S. N., Makhmudova, K. D., & Ortikova, S. X. (2023). Features of prevention of chronic kidney diseases and chronic heart failure. Science and Education, 4(5), 242-250.

Khusainova, M. A., Khaydarov, S. N., Makhmudova, K. D., & Nayimov, A. S. (2023). Prevalence of bronchiolitis in patients with Rheumatoid arthritis. Science and Education, 4(5), 232-241.

Alisherovna, K. M., Toshtemirovna, E. M. M., Duskobilovich, B. S., & Umirxanovna, K. G. (2022). DYSFUNCTION LEFT VENTRICULAR IN BRONCHIAL ASTHMA. Spectrum Journal of Innovation, Reforms and Development, 4, 216-221.

Alisherovna, K. M., Toshtemirovna, E. M. M., & Oybekovna, E. E. (2022). Quality of life of patients with cirrhosis of the liver. Spectrum Journal of Innovation, Reforms and Development, 4, 197-202.

Alisherovna, K. M., Kairatovna, R. A., Umirovna, I. S., & Oybekovich, T. M. (2023). CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ANEMIA. Spectrum Journal of Innovation, Reforms and Development, 21, 140-147.

Khabibovna, Y. S., & Alisherovna, K. M. (2024). STRESS TESTING IN PATIENTS WITH CORONARY HEART DISEASE. Journal of new century innovations, 45(3), 28-33.

Alisherovna, K. M., Kulmuxammatovich, Y. U., Boymamatovna, E. F., & Shokirovich, S. A. (2023). THE STATE OF NEUROPEPTIDE-CYTOKINE STATUS IN ISCHEMIC HEART DISEASE. Spectrum Journal of Innovation, Reforms and Development, 11, 42-50.

Alisherovna, K. M., Nizamitdinovich, K. S., Rustamovich, T. D., & Haqnazarovich, K. S. (2022). Mental Status and Quality of Life in Patients With Sinus Node Weakness Syndrome and Chronic Coronary Heart Failure of Ischemic Etiology. Texas Journal of Medical Science, 15, 78-82.

Alisherovna, K. M., Erkinovna, K. Z., Djamshedovna, K. D., & Nizamitdinovich, K. S. (2023). QUALITY OF LIFE PATIENTS WITH OSTEOARTHRITIS. Journal of new century innovations, 36(1), 164-175.

Alisherovna, K. M., Davranovna, M. H., & Nizametdinovich, K. S. (2022). Chronic heart failure in women. Central Asian Journal of Medical and Natural Science, 3(1), 21-25.

Alisherovna, K. M., & Djamshedovna, K. D. (2024). AFTER COVID-19 QUALITY OF LIFE. Spectrum Journal of Innovation, Reforms and Development, 25, 103-110.

Alisherovna, K. M., Erkinovna, K. Z., Davranovna, M. K., & Pulotovna, Z. D. (2022). Positive Effect of Sorbitol in Patients with Chronic Renal Insufficiency. Miasto Przyszłości, 30, 214-217.

Alisherovna, K. M. (2021). DISORDERS OF KIDNEY AND LIVER FUNCTION IN HEART FAILURE. POLISH SCIENCE JOURNAL, 156.

Alisherovna, K. M., Akmalovna, K. N., & Mamasoliyevna, D. N. (2022). Kidney dysfunction in chronic heart failure. Texas Journal of Medical Science, 13, 104-109.

Baxtiyorovich, U. J., Alisherovna, K. M., & Mamasoliyevna, D. N. (2023). Features of cognitive impairment in patients with chronic kidney disease at predialysis stages. World Bulletin of Public Health, 22, 49-54.

Khabibovna, Y. S., Alisherovna, K. M., Erkinovna, K. Z., & Djamshedovna, K. D. (2023). Gender Characteristics of the Course of Rheumatoid Arthritis. Miasto Przyszłości, 40, 438-442.

Erkinovna, K. Z., Alisherovna, K. M., Bakhtiyorovich, U. J., & Djamshedovna, K. D. (2023). METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS. Journal of new century innovations, 38(2), 203-211.

Alisherovna, K. M., Baxtiyorovich, Z. M., & Anvarovich, N. J. (2022). To Assess The Condition Of The Myocardium In Patients Chronic Heart Failure On The Background Of Rheumatoid Arthritis. Spectrum Journal of Innovation, Reforms and Development, 4, 210-215.

Alisherovna, K. M., Toshtemirovna, E. M. M., Djamshedovna, K. D., & Maxammadiyevich, K. S. (2022). Endothelial Dysfunction in Patients with Chronic Heart Failure. Miasto Przyszłości, 30, 218-220.

Alisherovna, K. M., Akramovna, I. K., & Yorkinovna, E. N. (2024). CLINICAL AND MORPHOLOGICAL CRITERIA OF COLITIS IN PATIENTS WITH CHRONIC ISCHEMIC DISEASE OF THE DIGESTIVE SYSTEM. Ta'lim innovatsiyasi va integratsiyasi, 18(6), 6-13.

Alisherovna, K. M., Akramovna, I. K., & Kairatovna, R. A. (2024). THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH OSTEOARTHRITIS WITH CARDIOVASCULAR DISORDERS IN METABOLIC SYNDROME. Ta'lim innovatsiyasi va integratsiyasi, 18(5), 223-230.

Akramovna, I. K., & Alisherovna, K. M. (2024). CAUSES OF ARRHYTHMIA DURING PREGNANCY. Journal of new century innovations, 45(3), 34-41.

Mamasoliyevna, D. N., Akmalovna, K. N., & Alisherovna, K. M. (2022). Quality of Life Depending on Gender. The Peerian Journal, 11, 71-77.

Mamasoliyevna, D. N., Alisherovna, K. M., & Totlibayevich, Y. S. (2023). Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: the Facets of Conjugacy. Miasto Przyszłości, 35, 166-173.

Alisherovna, K. M., Akramovna, I. K., & Baxtiyorovna, O. K. (2024). THE COURSE OF CHRONIC ISCHEMIC PANCREATITIS IN PATIENTS WITH CORONARY HEART DISEASE. Ta'lim innovatsiyasi va integratsiyasi, 18(5), 231-239.

Alisherovna, K. M., & Yusupovich, N. F. (2021). FEATURES OF THE CIRCADIAN RHYTHM BLOOD PRESSURE IN PATIENTS HEART FAILURE AND IMPAIRED RENAL FUNCTION. EDITOR COORDINATOR, 423.

Alisherovna, K. M., Sherzodovna, M. D., Tursunboyevna, I. K., & Uktamovna, U. U. (2023). LEFT VENTRICULAR HYPERTROPHY IN PERSONS WITHOUT ARTERIAL HYPERTENSION: PSYCHOSOMATIC APPROACH TO THE STUDY OF THIS PHENOMENON.

Alisherovna, M. K. Stages Of Development Of Renal Dysfunction And Anemia In Patients With Chronic Heart Failure. International Journal of Innovations in Engineering Research and Technology, 8(05), 50-53.

Alisherovna, K. M., Akramovna, I. K., Bakhtiyorovich, U. J., Nizamitdinovich, K. S., Jasurovna, J. S., Kairatovna, R. A., & Abdukholikovna, E. S. (2023). Exacerbations of chronic obstructive pulmonary disease and coronary atherosclerosis. Journal of new century innovations, 39(1), 176-178.

Akramovna, I. K., Rafikovna, U. K., & Ergashevna, E. N. (2024). Current Perceptions of Chronic Pancreatitis. International Journal of Alternative and Contemporary Therapy, 2(1), 12-16.

Исломова, К. А., & Тоиров, Э. С. (2020). Эффективность внутрисуставного введения хондропротекторов при раннем остеоартрозе. Вестник науки и образования, (9-3 (87)), 92-97.

Khusainova, M. A., Ergashova, M. M., Eshmamatova, F. B., & Khayitov, S. M. (2023). Features of quality of life indicators in patients with pneumonia. Science and Education, 4(2), 138-144.